MedTrace Logo

BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer

NCT00049244 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2017-01-30

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining BMS-247550 with capecitabine in treating patients who have metastatic breast cancer that has not responded to previous chemotherapy with a taxane and an anthracycline.

Conditions

Interventions

DRUG

capecitabine

DRUG

ixabepilone

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • R-Pharm

    lead INDUSTRY

Principal Investigators

  • Linnea Chap, MD · Jonsson Comprehensive Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00049244 on ClinicalTrials.gov